Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Smruthi OrganicsBOM:540686 -0.87%62 EV-to-EBIT is 16.28 as of Sep. 12, 2026, which is 1% below its 10-year median of 16.41. GuruFocus rates BOM:540686 with a GF Score™ of 62/100 and a GF Value™ of ₹124.07 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 683 Drug Manufacturers companies, Smruthi Organics ranks worse than 50.66% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Smruthi Organics's Enterprise Value for the quarter that ended in Jun. 2026 was ₹1,336 Mil.
Smruthi Organics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹117 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smruthi Organics EV-to-EBIT Related Terms
Smruthi Organics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Smruthi Organics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Smruthi Organics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smruthi Organics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Smruthi Organics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Smruthi Organics's EV-to-EBIT falls into.
Smruthi Organics's current Enterprise Value is ₹1,901 Mil.
Smruthi Organics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹117 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smruthi Organics (BOM:540686) has a EV-to-EBIT of 16.28 as of Sep. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Smruthi Organics and its competitors. This is near median its historical median of 16.41. According to the industry distribution chart, Smruthi Organics ranks #346 out of 683 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Smruthi Organics' EV-to-EBIT too high?
Smruthi Organics' current EV-to-EBIT of 16.28 is near median its 10-year median of 16.41. The Drug Manufacturers industry median EV-to-EBIT is 16.13. Smruthi Organics' value of 16.28 is 0.9% above this industry median. Based on the distribution chart, Smruthi Organics ranks #346 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Smruthi Organics has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Smruthi Organics' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Smruthi Organics ranks #346 out of 683 companies for EV-to-EBIT. This places Smruthi Organics in the lower half of its industry. The industry median EV-to-EBIT is 16.13. Smruthi Organics' value of 16.28 is 0.9% above this benchmark. While the company's 10-year median is 16.41 vs. the industry median of 16.13, Smruthi Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.13, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smruthi Organics's current EV-to-EBIT of 16.28 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Smruthi Organics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smruthi Organics's current EV-to-EBIT is 16.28, which is near median its own 10-year median of 16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smruthi Organics stock overvalued right now?
Based on GuruFocus' analysis, Smruthi Organics (BOM:540686) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹124.07, compared to a current price of ₹160.10 — trading 29% above its estimated fair value. The current EV-to-EBIT is 16.28, which is near median its 10-year median of 16.41 and 0.9% above the Drug Manufacturers industry median of 16.13. Smruthi Organics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Smruthi Organics (BOM:540686), the current EV-to-EBIT is 16.28 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smruthi Organics (BOM:540686) Overvalued in 2026?
Based on GuruFocus' analysis, Smruthi Organics stock appears to be overvalued.
The current stock price of ₹160.10 is trading 29% above its estimated GF Value™ of ₹124.07.
GuruFocus considers Smruthi Organics to be Modestly Overvalued.
Key valuation signals for BOM:540686:
EV-to-EBIT: 16.28 (near median its 10-year median of 16.41)
GF Value™: ₹124.07 vs. price of ₹160.10 (29% above fair value)
Industry Position: 0.9% above the Drug Manufacturers median (#346 of 683)
No single metric tells the full story. See the BOM:540686 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smruthi Organics Ltd is engaged in the manufacture of bulk drugs and drug intermediates (API Products). The product portfolio includes Amlodipine Besilate, Amlodipine Base, S-Amlodipine Besilate, S-Amlodipine Base, Norfloxacin, Metformin HCI, Diloxanide Furoate, Phthaloyl Amlodipine, Pantoprazole Sodium, Pefloxacin Mesylate Dihydrate, Telmisartan, Losartan Potassium, and many more. It has two reportable business segments: Bulk Drugs and Drugs Intermediates (API), and Formulation. It generates the majority of its revenue from the Bulk Drugs and Drugs Intermediates (API) segment. Geographically, the company generates maximum revenue from outside India through exports, and the rest from its business within India.
62GF Score
Get the complete analysis for BOM:540686
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540686 has been successfully added to your 
